Literature DB >> 30932299

The experience of combined and sequential liver and kidney transplantation from a single living donor in patients with primary hyperoxaluria type 1.

Ali Ozer1, Hikmet Aktas1, Burcu Bulum2, Remzi Emiroglu1.   

Abstract

LKT is the only effective treatment for PH1 because it replaces both the source (liver) and the target (kidney) of the disease. Most studies report on LKT in patients with PH1 from deceased donors. This study reports on five patients who underwent LKT from a single living  donor between April 2017 and March 2018. Combined LKT was performed for 1 patient and sequential LKT for the remainder. The median age of the patients at the time of diagnosis and transplantation was 5.5 (0.3-18) and 10 (6-21) years, respectively. All patients received left lateral liver segment transplantation, except one patient who received right liver lobe transplantation. No liver graft loss was observed, and liver function tests were stable at the final evaluation of all patients. Renal function tests of the patients were also stable at the final assessment, except for the young adult patient. None of the patients suffered from acute rejection. One patient died at the second month following liver transplantation due to severe pneumonia and sepsis. This study concludes that combined or sequential LKT from a single living donor can be safely performed and provides encouraging results for even the youngest and smallest patients with PH1.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Primary hyperoxaluria; kidney transplantation; liver transplantation; living donor

Mesh:

Year:  2019        PMID: 30932299     DOI: 10.1111/petr.13406

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  6 in total

1.  Extreme living donation: A single center simultaneous and sequential living liver-kidney donor experience with long-term outcomes under literature review.

Authors:  Yücel Yankol; Cihan Karataş; Turan Kanmaz; Burak Koçak; Münci Kalayoğlu; Koray Acarlı
Journal:  Turk J Surg       Date:  2021-09-28

2.  Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the scientific registry of transplant recipients database.

Authors:  Jie Xiang; Zheng Chen; Fangshen Xu; Shengmin Mei; Zhiwei Li; Jie Zhou; Yinlei Dong; Yangjun Gu; Zhichao Huang; Zhenhua Hu
Journal:  BMC Gastroenterol       Date:  2020-07-03       Impact factor: 3.067

3.  Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry.

Authors:  Elisabeth L Metry; Sander F Garrelfs; Hessel Peters-Sengers; Sally-Anne Hulton; Cecile Acquaviva; Justine Bacchetta; Bodo B Beck; Laure Collard; Georges Deschênes; Casper Franssen; Markus J Kemper; Graham W Lipkin; Giorgia Mandrile; Nilufar Mohebbi; Shabbir H Moochhala; Michiel J S Oosterveld; Larisa Prikhodina; Bernd Hoppe; Pierre Cochat; Jaap W Groothoff
Journal:  Kidney Int Rep       Date:  2021-11-26

4.  Hyperoxaluria: An early diagnosis will allow a timely combined renal and liver transplantations to avoid irreversible damages to all other organs.

Authors:  Elisa Kottos; Brigitte Adams; Dominique Biarent; Xavier Beretta-Piccoli; Khalid Ismaili; David De Bels; Patrick M Honore; Sebastien Redant
Journal:  J Transl Int Med       Date:  2021-12-31

5.  Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.

Authors:  Elisabeth L Metry; Liza M M van Dijk; Hessel Peters-Sengers; Michiel J S Oosterveld; Jaap W Groothoff; Rutger J Ploeg; Vianda S Stel; Sander F Garrelfs
Journal:  Pediatr Nephrol       Date:  2021-04-08       Impact factor: 3.714

6.  Deceased vs living donor grafts for pediatric simultaneous liver-kidney transplantation: A single-center experience.

Authors:  Sergey Gautier; Artem Monakhov; Olga Tsiroulnikova; Mikhail Voskanov; Igor Miloserdov; Timur Dzhanbekov; Sergey Meshcheryakov; Robert Latypov; Elena Chekletsova; Olga Malomuzh; Khizri Khizroev; Deniz Dzhiner; Irina Pashkova
Journal:  J Clin Lab Anal       Date:  2020-01-22       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.